Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of chronic stable angina or at least 3 months prior to screening, with at least 1 angina episode per month
Ischemic heart disease documented by myocardial infarction, coronary angiography or a revascularization procedure
Receiving stable doses of cardiac medication
Completes 2 exercise treadmill tests during screening meeting protocol requirements
You may not be if
Participating in another investigational study
Current or prior malignancy within 5 years of randomization
Known sensitivity to any components of the investigational product
Not able to complete all protocol required study visits
Having the following within 3 months prior to or during screening: Unstable angina or acute coronary syndrome, transient Ischemic attack (TIA) or stroke, revascularization procedure, or instability in ST-segment depression between screening exercise treadmill tests, as assessed by the core electrocardiograph (ECG) laboratory
Clareo Health | Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
